Salmeterol

CAS: 89365-50-4

Rif. 3D-FS46783

Informazioni sul prodotto

• Nome: Salmeterol
• Sinonimi: 2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-phenol, 1,3-Benzenedimethanol, 4-hydroxy-α¹-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol, 2-Hydroxymethyl-4-[1-hydroxy-2-[6-(4-phenyl-butoxy)-hexylamino]-ethyl]-phenol, 4-Hydroxy-α¹-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol, Cgp 54103, Gr 33343X, 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, 1,3-Benzenedimethanol, 4-hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (±)-, 4-Hydroxy-α1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol

Descrizione

Salmeterol is a long-acting bronchodilator that binds to eosinophil cationic protein and decreases inflammation. It is used in combination with fluticasone for the treatment of asthma. Salmeterol also has anti-inflammatory properties, which may be due to its binding to the glucocorticoid receptor and inhibition of prostaglandin synthesis. The drug binds to sodium citrate and xinafoate in vitro and may have an effect on cardiac function. Salmeterol is available as the xinafoate salt, salmeterol xinafoate, which is a prodrug that is hydrolyzed in vivo to salmeterol. This drug binds to the glucocorticoid receptor, leading to decreased inflammation by inhibiting the production of prostaglandin E2 and leukotriene B4. Salmeterol also causes relaxation of bronchial smooth muscle cells by activating potassium channels associated with their membrane potentials

• Marchio: Biosynth

Proprietà chimiche

• Peso molecolare: 415.57 g/mol
• Formula: C₂₅H₃₇NO₄
• Purezza: Min. 95%
• Colore/Forma: Powder
• InChI: InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
• InChI key: InChIKey=GIIZNNXWQWCKIB-UHFFFAOYSA-N
• SMILES: OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O